Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease

Centre Hospitalier Universitaire, Amiens1 site in 1 country159 target enrollmentOctober 28, 2013

ConditionsInflammatory Bowel Diseases NT-pro-BNP

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Inflammatory Bowel Diseases
Sponsor: Centre Hospitalier Universitaire, Amiens
Enrollment: 159
Locations: 1
Primary Endpoint: Blood level of NTproBNP.
Status: Terminated
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

NT-proBNP is a major diagnostic and prognostic marker in cardiology, but it is also a new marker for biological inflammation, especially in rheumatology.

Its evaluation in chronic inflammatory bowel disease was carried out in a preliminary study, the OPERA study where in a population of 12 patients showed an increase in NT-proBNP correlated with the biological and endoscopic activity of the disease. This larger study is therefore a pilot study that could see NTproBNP as a new biomarker of inflammation in MICI.

Registry

clinicaltrials.gov

Start Date

October 28, 2013

End Date

August 7, 2017

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Centre Hospitalier Universitaire, Amiens

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Adult subjects (age 18 years)
•MICI Group: Patients monitored for probable HC or MC
•Control group: Patients referred for consultation in gastroenterology with a clinical and endoscopic picture eading to the diagnosis of TF I
•Person who agreed to participate in the study
•Patient covered by social insurance

Exclusion Criteria

•Causes of increased concentrations of natriuretic peptides: acute heart failure, acute or chronic pulmonary disease with right ventricular repercussion, valvulopathies, primary or secondary HVG, atrial fibrillation cardiac arrhythmia, chronic systolic dysfunction, hyperthyroidism, Addison's disease, hyperaldosteronism Primary, diabetes, cirrhosis with ascites, cancers, chronic renal insufficiency.
•Inflammatory and autoimmune diseases (excluding MC and RCH), chronic inflammatory syndrome
•Ongoing treatment that may affect the concentration of natriuretic peptides: ACE inhibitor, angiotensin II receptor antagonists, diuretics
•Patient deprived of liberty or protected major (under guardianship or curatorship)